KLRA Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $30.00. The high target offers 170.42% upside. The low target suggests 69.01% downside. The mean target is $38.00. This offers 114.08% upside. Kailera Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by 36.36%. The prior quarter beat by 470867.74%. Over the last six quarters, Apple has recorded several small beats. These include 470867.74% in May 26, 2026.

Average 10-day trading volume of 982.11 thousand shares is slightly above the 3-month average of 735.96 thousand, indicating heightened recent market interest.

Kailera Therapeutics, Inc. has 129.57 million shares outstanding. The public float is 58.40 million shares, elevated short interest at 4.95% of float. This equals 6.41 million shares. The short ratio is 5.54 days. Institutional investors hold 47.09% of the float. Insiders own 0.0%.

Our AI price prediction model suggests that Kailera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.68%, with price expected at $16.21 by September 07, 2026, within a range of $15.22 to $17.17 3-Month Outlook: Projected fall of -98.76%, reaching $0.22 by November 20, 2026, with a range of $0.11 to $0.35. 1-Year Outlook: Projected gain of 299.04%, with price at $70.83 by August 24, 2027, within a range of $70.66 to $71.05.

Valuation shows Kailera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.18. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $38.00, suggesting 114.08% upside. Our AI forecast model points to short-term weakness (-8.68% over two weeks), a medium-term fall (-98.76% over three months), and a longer-term gain (299.04% over one year), with expected trading ranges indicating moderate volatility.

Kailera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.27. This means the shares are trading above this model’s fair value.

Kailera Therapeutics, Inc. trades at a P/E ratio of -10.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.64 suggesting the stock is closer to book value. The P/FCF stands at -15.92, also below market averages.

Kailera Therapeutics, Inc. (NASDAQ:KLRA) closed at $17.75 USD, gaining $1.21 (7.32%) from the previous close of $16.54. The stock is currently mid-range between its 52-week high and low $16.37 and $28.23. With a market capitalization of about $2.30 billion, Kailera Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 722.25 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Kailera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ronald C. Renaud Jr., the company employs approximately 145 people and listed since April 17, 2026. Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments.